64x Bio Launches LV Apex Suite, Expanding Its CellMap-Driven VectorSelect Platform Into Lentiviral Vector Production
64x Bio, a biotech company developing scalable solutions for the production of advanced therapies, today announced the launch of LV Apex Suite, a new product line designed to support high performance lentiviral vector manufacturing.
64x Bio Launches AAV Apex Suite to Power the Next Generation of Gene Therapy Manufacturing
64x Bio, a biotech company developing scalable solutions for the production of advanced therapies, today announced the launch of AAV Apex Suite, a high yield product line designed to meet one of the most urgent bottlenecks in gene therapy — manufacturing.
64x Bio Raises $55 Million Series A Financing to Advance Cell Line Engineering Platform for Gene Therapy Manufacturing
64x Bio, a synthetic biology company, today announced the close of a $55 million Series A financing round to fund the expansion of its VectorSelect™ platform, a novel cell line engineering technology which has the potential to revolutionize the economics and accessibility of gene therapy.
